Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$204.45
+1.1%
$219.31
$193.03
$251.99
$58.70B0.351.73 million shs1.34 million shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$101.13
+2.2%
$98.85
$70.97
$107.17
$149.58B0.736.41 million shs8.98 million shs
Medtronic plc stock logo
MDT
Medtronic
$84.24
+0.6%
$88.36
$75.96
$96.25
$108.04B0.796.67 million shs5.96 million shs
ResMed Inc. stock logo
RMD
ResMed
$236.11
+10.1%
$221.75
$179.00
$263.05
$34.68B0.751.03 million shs2.26 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+1.21%+0.87%-11.66%-15.75%-13.64%
Boston Scientific Co. stock logo
BSX
Boston Scientific
+4.26%+3.91%-3.63%-2.61%+43.51%
Medtronic plc stock logo
MDT
Medtronic
+0.43%+1.21%-7.11%-6.21%+3.04%
ResMed Inc. stock logo
RMD
ResMed
+0.18%+1.42%-3.66%-13.70%+16.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.8441 of 5 stars
3.53.04.24.03.53.31.3
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.418 of 5 stars
3.53.00.04.23.32.51.3
Medtronic plc stock logo
MDT
Medtronic
4.7477 of 5 stars
3.25.03.34.03.52.50.6
ResMed Inc. stock logo
RMD
ResMed
4.3059 of 5 stars
3.31.03.34.62.11.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
3.00
Buy$272.8633.46% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
3.04
Buy$112.8711.61% Upside
Medtronic plc stock logo
MDT
Medtronic
2.44
Hold$96.1414.13% Upside
ResMed Inc. stock logo
RMD
ResMed
2.60
Moderate Buy$254.317.71% Upside

Current Analyst Ratings Breakdown

Latest RMD, BSX, MDT, and BDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$274.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$113.00 ➝ $115.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$116.00 ➝ $120.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$113.00 ➝ $117.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$110.00 ➝ $112.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$115.00 ➝ $120.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$247.00 ➝ $255.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$290.00 ➝ $285.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$286.00 ➝ $290.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$260.00 ➝ $248.00
4/23/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.64B2.84$19.00 per share10.76$89.57 per share2.28
Boston Scientific Co. stock logo
BSX
Boston Scientific
$16.75B8.93$3.50 per share28.86$14.91 per share6.78
Medtronic plc stock logo
MDT
Medtronic
$33.20B3.25$6.90 per share12.21$38.69 per share2.18
ResMed Inc. stock logo
RMD
ResMed
$4.93B7.04$9.36 per share25.23$35.77 per share6.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$6.0233.9613.071.638.47%15.74%7.29%5/1/2025 (Estimated)
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.85B$1.2580.9031.312.7911.07%17.80%9.85%N/A
Medtronic plc stock logo
MDT
Medtronic
$3.68B$3.2925.6014.452.2212.83%14.07%7.70%5/21/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.4727.8822.791.5325.34%26.17%18.60%N/A

Latest RMD, BSX, MDT, and BDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2025
Medtronic plc stock logo
MDT
Medtronic
$1.58N/AN/AN/A$8.81 billionN/A
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28N/AN/AN/A$5.35 billionN/A
4/23/2025Q1 2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.67$0.75+$0.08$0.45$4.57 billion$4.66 billion
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.37$2.37N/A$2.48$1.28 billion$1.29 billion
2/18/2025Q3 2025
Medtronic plc stock logo
MDT
Medtronic
$1.36$1.39+$0.03$1.01$8.33 billion$8.29 billion
2/5/2025Q1 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.00$3.43+$0.43$1.04$5.13 billionN/A
2/5/2025Q4 2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.65$0.70+$0.05$0.38$4.42 billionN/A
1/30/2025Q2 2025
ResMed Inc. stock logo
RMD
ResMed
$2.29$2.43+$0.14$2.34$1.27 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.03%+5.00%69.10%53 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
$2.803.32%+4.14%85.11%48 Years
ResMed Inc. stock logo
RMD
ResMed
$2.120.90%+7.63%25.03%13 Years

Latest RMD, BSX, MDT, and BDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
3/6/2025
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.703%3/28/20253/28/20254/11/2025
1/28/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.041.67%3/10/20253/10/20253/31/2025
1/30/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%2/13/20252/13/20253/20/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.69
1.13
0.63
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.41
1.08
1.02
Medtronic plc stock logo
MDT
Medtronic
0.48
1.90
1.39
ResMed Inc. stock logo
RMD
ResMed
0.13
3.33
2.29

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
Medtronic plc stock logo
MDT
Medtronic
82.06%
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
Medtronic plc stock logo
MDT
Medtronic
0.20%
ResMed Inc. stock logo
RMD
ResMed
0.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
77,000287.14 million286.10 millionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
45,0001.48 billion1.47 billionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable
ResMed Inc. stock logo
RMD
ResMed
8,160146.87 million145.82 millionOptionable

Recent News About These Companies

ResMed: Cornering The Market In Sleep Solutions
Q3 2025 Resmed Inc Earnings Call Transcript
ResMed reports Q3 non-GAAP EPS $2.37, consensus $2.36
ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript
ResMed posts Street-beating Q3
ResMed Inc. 2025 Q3 - Results - Earnings Call Presentation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$204.45 +2.13 (+1.05%)
As of 03:59 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$101.13 +2.21 (+2.23%)
As of 03:59 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Medtronic stock logo

Medtronic NYSE:MDT

$84.24 +0.49 (+0.59%)
As of 03:59 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

ResMed stock logo

ResMed NYSE:RMD

$236.11 +21.67 (+10.11%)
As of 03:59 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.